Italian Journal of Dermatology and Venereology最新文献

{"title":"Comparing adalimumab biosimilars in the clinical practice of psoriatic patients.","authors":"Domenico Giordano, Antonio Di Guardo, Annamaria Larosa, Andrea Vizzaccaro, Giulia Maretti, Federica Rega, Flavia Persechino, Nazareno Gagliostro, Severino Persechino","doi":"10.23736/S2784-8671.24.07914-3","DOIUrl":"https://doi.org/10.23736/S2784-8671.24.07914-3","url":null,"abstract":"<p><strong>Background: </strong>Biologic drugs have revolutionized the treatment of psoriasis and other chronic inflammatory diseases. In recent years, numerous biosimilar molecules that target cytokines such as TNF-alpha or its receptors have been developed. The approval of biosimilars has made it possible to reduce the costs of biologic drugs, thereby increasing access to these therapies for more patients and enhancing psoriasis treatment globally. Imraldi and Idacio are both biosimilars of Adalimumab, approved for treating moderate to severe psoriasis.</p><p><strong>Methods: </strong>Our study aims to compare these two adalimumab biosimilars in psoriasis patients who have previously undergone treatment with other biologic drugs or systemic therapy in a real-life setting. Our cohort comprised 32 psoriatic patients. Of these patients, 15 were prescribed Imraldi, while the remaining were on Idacio. To assess the efficacy of these therapies, we utilized various measures including the Psoriasis Area and Severity Index, the Pruritus Visual Analog Scale, the Visual Analog Scale, the Dermatology Life Quality Index, and the Psoriasis Global Assessment, monitoring the patients over a 24-week period.</p><p><strong>Results: </strong>Our results indicated that the use of Idacio led to greater decreases in all scores compared to Imraldi. However, in terms of safety and efficacy, the two drugs were found to be comparable.</p><p><strong>Conclusions: </strong>The findings of this study support the efficacy and safety of Idacio and Imraldi in managing psoriasis, with Idacio demonstrating superior efficacy in reducing disease severity. Future studies could benefit from expanding the patient cohort and conducting further analyses to evaluate individual responses to treatment.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"159 6","pages":"599-606"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical granulomatosis with polyangiitis.","authors":"Silvia Borriello, Sara Boskovic, Elena Marra, Chiara Astrua, Niccolò Siliquini, Michela Bellocchia, Luca Mastorino, Nadia Sciamarrelli, Paolo Dapavo, Luca Conti, Giulia Vocino Trucco, Simone Ribero, Pietro Quaglino","doi":"10.23736/S2784-8671.24.08100-3","DOIUrl":"10.23736/S2784-8671.24.08100-3","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"688-689"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142835956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lichenoid drug eruption during treatment with brodalumab for psoriasis.","authors":"Nadia Sciamarrelli, Luca Mastorino, Martina Merli, Sara Susca, Sara Boskovic, Silvia Borriello, Paolo Dapavo, Simone Ribero, Pietro Quaglino","doi":"10.23736/S2784-8671.24.08051-4","DOIUrl":"https://doi.org/10.23736/S2784-8671.24.08051-4","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"159 6","pages":"684-685"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term treatment with risankizumab of palmoplantar pustulosis and acrodermatitis continua of hallopeau.","authors":"Maria Esposito, Paolo Antonetti, Andrea De Berardinis, Emanuele Vagnozzi, Maria Concetta Fargnoli","doi":"10.23736/S2784-8671.24.07932-5","DOIUrl":"10.23736/S2784-8671.24.07932-5","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"692-693"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Televisits for patients with atopic dermatitis treated with dupilumab: experience from a tertiary care center in Northern Italy.","authors":"Luca Mastorino, Gitana Scozzari, Simone Ribero, Pietro Quaglino, Antonio Scarmozzino, Michela Ortoncelli","doi":"10.23736/S2784-8671.24.07974-X","DOIUrl":"10.23736/S2784-8671.24.07974-X","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is an inflammatory skin disease. The monoclonal antibody dupilumab can provide a rapid response with achievement of stable clinical disease. This study aimed to confirm the effectiveness of a televisit approach for patients with AD and treated with dupilumab.</p><p><strong>Methods: </strong>Demographic data and characteristics at baseline including mean EASI, mean NRSp, mean DLQI, and mean NRSds were retrospectively assessed and subsequently collected at up to 48 weeks, last visit in attendance, and up to the fourth televisit. The mean reduction of the above scores, and achievement at each time point of EASI≤7, EASI 75, EASI 90, DLQI 0/1, and NRSp≤4 were considered as endpoints.</p><p><strong>Results: </strong>Twelve patients underwent at least 1 televisit. The mean follow-up on dupilumab before switching to a televisit was 28.5 months. The mean EASI at the last face-to-face visit was 0.75 and remained stable at subsequent televisit visits. All patients achieved EASI≤7 as early as week 16 which was during the televisits. A similar trend was seen for EASI 75. Only 1 patient discontinued the televisits after 2 visits, preferring to return in person.</p><p><strong>Conclusions: </strong>In our case series of remotely-followed patients, clinical and patient-reported outcomes remained stable.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"612-617"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142836421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost per responder analysis of abrocitinib versus dupilumab in moderate to severe atopic dermatitis.","authors":"Martina Maurelli, Giampiero Girolomoni, Paolo Gisondi","doi":"10.23736/S2784-8671.24.07946-5","DOIUrl":"10.23736/S2784-8671.24.07946-5","url":null,"abstract":"<p><strong>Background: </strong>The JADE COMPARE was a multicenter, phase 3 randomized, double-blind, placebo-controlled trial with the objective of comparing the 16-week efficacy and safety of oral abrocitinib 100 or 200 mg once daily, dupilumab 300 mg subcutaneous injection every 2 weeks, or placebo in adults with moderate-to-severe atopic dermatitis (AD). Pharmacoeconomic evaluation of these new drugs for AD is lacking. The objective of our study was to compare the cost per responder of abrocitinib versus dupilumab in patients with AD using the data from the JADE COMPARE trial.</p><p><strong>Methods: </strong>The cost per responder was calculated by multiplying the cost of treatment by the number needed to treat for each therapy, as obtained from the JADE COMPARE trial. The 12-week primary endpoint was the Investigator global assessment (IGA) 0/1 and eczema area and severity index improvement of at least 75% (EASI75) response rate. The key secondary end points were itch response (defined as an improvement of ≥4 points in the score on the Peak Pruritus Numerical Rating Scale [PP-NRS; scores range from 0 to 10]) at week 2 and IGA and EASI-75 responses at week 16. The cost per responder model was based on the perspective of the Italian National Health System. Regarding the costs of drugs, ex-factory wholesale purchase prices were used, including the mandatory discounts according to the national legislation (5% discount, plus a further 5% reduction on the discount result). Abrocitinib 100 mg and 200 mg have flat price in Italy.</p><p><strong>Results: </strong>The 12-week IGA 0/1 cost per responder was € 3955.77 and € 2984.94 for abrocitinib 100 mg and 200 mg, respectively, versus € 7467.96 for dupilumab; as for 12-week EASI75 the cost were € 2463.30 and € 2057.58 vs. € 4705.09, respectively. As far as the secondary end points, the costs per responder were always lower for abrocitinib 100 and 200 mg compared to dupilumab, including the PP-NRS (€ 3791.55 and € 2451.22, vs. € 6462.65), the IGA 0/1 at week 16 (€ 6931.05 and € 4854.15 vs. € 8787.85) and the EASI75 at week 16 (€ 3984.75 and € 3381.00 vs. € 5197.45).</p><p><strong>Conclusions: </strong>According to JADE COMPARE trial data, the costs per responder of abrocitinib were considerably lower than dupilumab. The results of the study are limited to the short time frame of JADE COMPARE trial.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"607-611"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First cases of contact injury following brown marmorated stink bug crush in Italy.","authors":"Moreno Dutto, Edoardo Cammarata, Giuseppe Lauria, Andrea Drago, Elia Esposto, Paola Savoia","doi":"10.23736/S2784-8671.24.07878-2","DOIUrl":"10.23736/S2784-8671.24.07878-2","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"689-691"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life experience with dupilumab in 56 children and adolescents aged 2 to 17 with uncontrolled moderate-to-severe atopic dermatitis.","authors":"Cristiana Colonna, Nicola A Monzani, Eleonora Quattri, Francesca Montefusco, Riccardo Cavalli","doi":"10.23736/S2784-8671.24.07940-4","DOIUrl":"10.23736/S2784-8671.24.07940-4","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"694-695"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translation and pre-validation of the Quality of Life in Hand Eczema Questionnaire (QOLHEQ) in Italian.","authors":"Rosella Gallo, Luca Stingeni, Monica Corazza, Ilaria Trave, Silvia M Ferrucci, Emanuela Martina, Maddalena Napolitano, Caterina Foti, Fabrizio Guarneri","doi":"10.23736/S2784-8671.24.08026-5","DOIUrl":"10.23736/S2784-8671.24.08026-5","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"682-684"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risankizumab in very elderly patients in real-world practice.","authors":"Elisa Lorenzoni, Antonella Di Cesare, Elia Rosi, Emanuele Trovato, Leonardo Pescitelli, Salvatore Panduri, Federica Ricceri, Susanna Rossari, Michela Magnano, Imma Savarese, Gionata Buggiani, Barbara Simoni, Nicola Milanesi, Flavia Manzo Margiotta, Alessandra Michelucci, Eugenio Capalbo, Martina Dragotto, Marco Romanelli, Pietro Rubegni, Francesca Prignano","doi":"10.23736/S2784-8671.24.07941-6","DOIUrl":"10.23736/S2784-8671.24.07941-6","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"695-696"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}